TTrialPathMatch Me to Trials
← Back to trials
RecruitingProstate Cancer

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT

Eligible age

40+ yrs

Accepts

Men

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation therapy (ADT) .

Sponsor: Indiana University

You may qualify if…

  • ✓ 1. Written informed consent and HIPAA authorization for release of personal health information
  • ✓ 2. Age ≥40 years at time of consent
  • ✓ 3. Previous diagnosis of prostate cancer who are either currently receiving ADT, or who are planning to start ADT for \>12 months
  • ✓ 4. Patients currently on or planned for treatment with ADT plus androgen pathway inhibitor (abiraterone, enzalutamide, apalutamide, darolutamide) are allowed
  • ✓ 5. ≥1 risk factor for ASCVD (hypertension, hyperlipidemia, diabetes, tobacco use)
  • ✓ 6. No current cardiac symptoms

You may not qualify if…

  • ✕ 1. Concurrent treatment with chemotherapy (docetaxel, cabazitaxel, mitoxantrone) at time of signing consent
  • ✕ 2. Patient has implantable cardioverter-defibrillator (ICD), or pacemaker
  • ✕ 3. History of coronary stents, obstructive coronary artery disease, myocardial infarction, coronary artery bypass grafting. History of atrial fibrillation
  • ✕ 4. Renal dysfunction with creatinine clearance \<35ml/min (calculated by Cockcroft-Gault Equation)
  • ✕ 5. Allergy to iodinated contrast
  • ✕ 6. Contraindication to the medications that may be given to regulate heart rate for the CCTA scan (applicable only to those randomized to the CCTA group)
  • ✕ 7. Patients taking sildenafil or tadalafil for vasodilation, pulmonary hypertension, or BPH
  • ✕ 1. Note: Subjects taking sildenafil or tadalafil for erectile disfunction will still be eligible.

Where it's recruiting

Indiana

Carmel · Indianapolis

Source: ClinicalTrials.gov · NCT05879913 · last updated 2026-10-05

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT · TrialPath